See the DrugPatentWatch profile for Inveltys
What is Inveltys (eye drop), and what is it used for?
Inveltys is a brand of corticosteroid eye drops used to treat inflammation in the eye after cataract surgery. It contains loteprednol etabonate, a steroid formulated for ocular use to reduce post-operative swelling and irritation [1].
What does the “1” mean (Inveltys 1)?
“Inveltys 1” most commonly refers to a specific strength and/or packaging formulation sellers list for the product (for example, “Inveltys 1%” or “Inveltys 1 eye drop” when describing the product line). The active ingredient is still loteprednol etabonate; the number typically points to the concentration/format rather than a different medicine [1].
How is Inveltys typically dosed after cataract surgery?
Post-cataract dosing schedules for steroid drops vary by prescriber and the exact product presentation, but they are generally tapered over time. Check the specific prescription label or the packaging insert for the exact frequency and taper instructions for your Inveltys version [1].
What side effects are patients most likely to ask about?
Like other steroid eye drops, Inveltys can cause side effects such as temporary blurred vision, eye irritation or burning, and increased eye pressure in some patients. It can also increase the risk of certain infections if used when infection is present. Patients are usually monitored after surgery if they need ongoing steroid treatment [1].
Is Inveltys the same as other steroid eye drops (for example, prednisolone-based brands)?
Inveltys and other post-operative steroid drops can differ by the specific active ingredient and formulation. Inveltys uses loteprednol etabonate, which is a corticosteroid designed for ocular inflammation control; dosing and risk profiles can differ slightly from other steroids used after eye surgery [1].
Who makes Inveltys, and is it protected by patents?
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines, and it can be a useful place to check the patent status of specific ophthalmic products like Inveltys as exclusivity and generic/alternate-product timelines evolve [2].
Sources
[1] https://www.drugs.com/inveltys.html
[2] https://www.drugpatentwatch.com/